Antibody response to inactivated hepatitis A vaccine

Hepatology Research

Volumn 9, Issue 2-3, 1997, Pages 103-112

  Tanaka, Eisuke ^a   Sata, Michio ^a   Nakano, Hitoshi ^a   Suzuki, Hiroshi ^a   Tanikawa, Kyuichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute hepatitis A; HAV antibody; Host factor; Seroconversion rate; Vaccine

Indexed keywords

HEPATITIS A VACCINE;

ACTIVE IMMUNIZATION; ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A; HOST RESISTANCE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION;

EID: 0031415651     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1386-6346(97)00079-x     Document Type: Article

References (19)

1. Ayoola EA. Viral hepatitis in Africa. In: Liss AR, editor. Viral Hepatitis and Liver Disease. New York, 1988:161-9.
2. Willcox M., Brohult J., Olsson I., Bengtsson E. Antibody to hepatitis A virus in Liberians (Letter). Trans Royal Soc Trop Med Hyg. 74:1980;690.
3. Wiedeman J.T., Moritugu Y., Miyamura K., Yamazaki S.et al. Seroepidemiology of hepatitis A virus in Japan. J Med Sci Biol. 40:1987;119-130.
4. Kimura M. Surveillance of infections in 1992 (in Japanese). Rinsho To Virus. 21:1993;28-37.
5. Kumashiro T., Sata M., Suzuki H., Ono K., Muraoka H.et al. A study of hepatitis A in elderly people. Acta Hepatol Jpn. 29:1988;457-562.
6. Muraoka H. Clinical and epidemiological study on factors of serious development of viral hepatitis A. Jpn J Gastroent. 87:1990;1383-1391.
7. Lino S., Fujiyama S., Horiuchi K.et al. Clinical trial of a lyophilized inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine. 10:1992;323-328.
8. Gerety R.J., Smallwood L.A., Finlayson J.S., Tabor E. Standardization of the antibody to hepatitis A virus (anti-HAV) content of immunoglobulin. Dev Biol Stand. 54:1983;411-416.
9. Wiedermann G., Ambrosch F., Andre F.E., D'Hondt E., Delem A., Safary A. Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine. 10((Suppl)1):1992;S129-131.
10. Werzberger A., Mensch B., Kuter B.et al. A controlled trial of a formalin inactivated hepatitis A vaccine in healthy children. N Engl J Med. 327:1992;453-457.
11. Pavia A.T., Nielsen L., Armington L.et al. A community-wide outbreak of hepatitis A in a religious community: Impact of mass administration of immune globulin. Am J Epidemiol. 131:1990;1085-1093.
12. Hall W.T., Madden D.L., Clarke N.A., Mundon F.K., Brandt D.E.L. Protective effect of immune serum globulin (ISG) against hepatitis A infection in a natural epidemic. Am J Epidemiol. 106:1977;72-75.
13. Fujiyama S., Lino S., Odoh K.et al. Time course of hepatitis A virus antibody titer after active and passive immunization. Hepatology. 15:1992;983-988.
14. Binn L.N., Bancroft W.H., Lemon S.M.et al. Preparation of a prototype inactivated hepatitis A vaccine from infected cell culture. J Infect Dis. 153:1986;749-756.
15. Provost P.J., Hilleman M.R. An inactivated hepatitis A virus vaccine prepared from infected marmoset liver. Proc Soc Exp Biol Med. 159:1978;201-203.
16. Flehmig B., Heinricy U., Pfisterer M. Immunogenicity of a killed hepatitis A vaccine in seronegative volunteers. Lancet. 13:1989;1039-1046.
17. Provost P.J., Banker F.S., Giesa P.A.et al. Progress toward a live, attenuated human hepatitis A vaccine (41387). Proc Soc Exp Biol Med. 170:1982;8-14.
18. Provost P.J., Bishop R.J., Gerety M.R.et al. New findings in live attenuated hepatitis A vaccine development. J Med Virol. 20:1986;165-175.
19. Midthun K., Ellerbeck E., Gershman K.et al. Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. J Infect Dis. 163:1991;735-739.